ESMO 2019: mCRC drug meets endpoints in Pfizer study
Pfizer has reported positive data from the interim analysis of the Phase III BEACON CRC clinical study conducted to assess…
All articles by Gujjarlapudi Satish
Gujjarlapudi Satish
-
-
Nucala minimises exacerbations in eosinophilic asthma patients
GlaxoSmithKline (GSK) has reported positive results from its study of Nucala (mepolizumab) in patients with severe eosinophilic asthma. Results were…
-
Astellas initiates trial to evaluate VMS therapy fezolinetant
Astellas Pharma has initiated the SKYLIGHT 1 Phase III trial to evaluate fezolinetant for the treatment of moderate-to-severe vasomotor symptoms…
-
Lilly reports positive data from CONQUER study of Emgality
Eli Lilly and Company has reported positive data from the Phase III CONQUER study of Emgality (galcanezumab-gnlm) in patients who…
-
Genentech reports positive data from cancer immunotherapy trial
Roche Group member Genentech has reported positive results from the Phase III IMvigor130 combination trial of Tecentriq (Atezolizumab) and platinum-based…
-
Pfizer’s RESET trial of rivipansel fails to meet endpoints
Pfizer’s Phase III Rivipansel (GMI-1070) Evaluating Safety, Efficacy and Time to Discharge (RESET) pivotal trial has failed to meet its…
-
Boehringer reports positive data from afatinib’s real-world study
Boehringer Ingelheim has reported positive interim results from the real-world GioTag study of afatinib (Giotrif/Gilotrif) in EGFR Del19 and T790M…
-
New respiratory syncytial virus vaccine shows promise in Phase I trial
An experimental vaccine developed by the National Institute of Allergy and Infectious Diseases (NIAID) to protect against respiratory syncytial virus…
-
AAV gene therapy shows positive results in Batten disease trial
Amicus Therapeutics has announced interim data from a Phase I/II clinical trial of an AAV gene therapy for the treatment…
-
Novartis’ Kisqali improves survival in MONALEESA-3 participants
Novartis has announced that the Phase III MONALEESA-3 study of Kisqali (ribociclib) has met its key secondary endpoint at interim…